Jeffrey W Schubert

US Patent:

20130084346, Apr 4, 2013

Filed:

Feb 28, 2011

Appl. No.:

13/582601

Inventors:

Scott Wolkenberg - Wyndmoor PA, US
James C. Barrow - Arnold MD, US
Michael S. Poslusney - Nashville TN, US
Scott T. Harrison - Glenside PA, US
B. Wesley Trotter - Medfield MA, US
James Mulhearn - Elkins Park PA, US
Kausik K. Nanda - Norristown PA, US
Peter J. Manley - Harleysville PA, US
Zhijian Zhao - Wilmington DE, US
Jeffrey W. Schubert - Ambler PA, US
Nathan Kett - Columbia TN, US
Amy Zartman - Hatfield PA, US

International Classification:

C07D 213/69
C07D 401/10
A61K 31/4439
C07D 213/73
C07D 213/74
C07F 5/02
A61K 31/69
A61K 31/444
C07D 401/14
C07D 471/04
A61K 31/4725
A61K 31/4709
A61K 45/06
C07D 413/10
A61K 31/5377
A61K 31/4545
C07D 417/10
A61K 31/541
C07D 413/12
A61K 31/4418

US Classification:

424722, 546296, 514348, 5462734, 514338, 546 13, 514 64, 546258, 514334, 546256, 514333, 546113, 514300, 546261, 514335, 546144, 514307, 546173, 514314, 514221, 544131, 5142355, 5462754, 514341, 5462774, 514339, 546194, 514318, 544 582, 5142278, 5462757

Abstract:

The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.

US Patent:

20230077499, Mar 16, 2023

Filed:

Dec 16, 2020

Appl. No.:

17/783870

Inventors:

- Rahway NJ, US
Andrew John Cooke - Scotland, GB
Robert Patrick Hayes - Lexington MA, US
Marc A. Labroli - Moorestown NJ, US
Michael Aaron Plotkin - Frenchtown NJ, US
Izzat Tiedje Raheem - Doylestown PA, US
Jeffrey W. Schubert - North Wales PA, US
David M. Tellers - Lansdale PA, US

Assignee:

Merck Sharp & Dohme LLC - Rahway NJ

International Classification:

A61K 31/4439
C07D 413/06
C07D 413/14
A61K 31/517
A61K 31/538
A61K 31/4725
A61K 31/4709
A61P 31/22
A61K 45/06

Abstract:

The present invention relates to novel Amido-Substituted Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein X, R, R, R, and Rare as defined herein. The present invention also relates to compositions comprising at least one Amido-Substituted Heterocycle Compound, and methods of using the Amido-Substituted Heterocycle Compounds for treating or preventing a herpesvirus infection in a patient.

US Patent:

20210395224, Dec 23, 2021

Filed:

Oct 24, 2019

Appl. No.:

17/286591

Inventors:

- Rahway NJ, US
- Shanghai, CN
Xiaolei Gao - Bridgewater NJ, US
Scott T. Harrison - Elkins Park PA, US
Timothy J. Henderson - Natick MA, US
Michael Man-Chu Lo - Bedminster NJ, US
Zhaoyang Meng - Ambler PA, US
James Mulhearn - Elkins Park PA, US
Vanessa L. Rada - Hatfield PA, US
Jeffrey W. Schubert - North Wales PA, US
Oleg B. Selyutin - West Windsor NJ, US
David M. Tellers - Lansdale PA, US
Ling Tong - Warren NJ, US
Fengqi Zhang - Edison NJ, US
Jianming Bao - South San Francisco CA, US
Chunsing Li - Shanghai, CN

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
MSD R&D (China) Co. LTD. - Shanghai

International Classification:

C07D 401/14
C07D 405/14

Abstract:

The present invention is directed to cinnolinyl and quinolinyl pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

US Patent:

20190315708, Oct 17, 2019

Filed:

Dec 18, 2017

Appl. No.:

16/471679

Inventors:

Jianming BAO - Shanghai, CN
Ronald FERGUSON - Rahway NJ, US
Xiaolei GAO - Bridgewater NJ, US
Scott HARRISON - West Point PA, US
Sandra L. KNOWLES - Kenilworth NJ, US
Michael Man-chu LO - Kenilworth NJ, US
Jeffrey W. SCHUBERT - West Point PA, US
- Rahway NJ, US
- Shanghai, CN

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 401/04
C07D 401/14
C07D 417/14
C07D 513/04
C07D 405/14
C07D 413/14
C07D 498/08
C07D 491/107

Abstract:

The present invention is directed to heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

US Patent:

20150299227, Oct 22, 2015

Filed:

Mar 27, 2015

Appl. No.:

14/671452

Inventors:

- Rahway NJ, US
James C. Barrow - Arnold MD, US
Michael S. Poslusney - Nashville TN, US
Scott T. Harrison - Glenside PA, US
Wesley B. Trotter - Medfield MA, US
James Mulhearn - Elkins Park PA, US
Kausik K. Nanda - Norristown PA, US
Peter J. Manley - Harleysville PA, US
Zhijian Zhao - Wilmington DE, US
Jeffrey W. Schubert - Ambler PA, US
Nathan R. Kett - Franklin TN, US
Amy Zartman - Hatfield PA, US

Assignee:

MERCK SHARP & DOHME CORP. - Rahway NJ

International Classification:

C07F 5/02
A61K 31/4418
C07D 401/04
A61K 31/4439
C07D 213/73
C07D 213/74
A61K 31/69
A61K 31/444
C07D 401/14
C07D 471/04
C07D 401/06
A61K 31/4725
A61K 31/4709
A61K 45/06
C07D 213/69

Abstract:

The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.